Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,187

Document Document Title
WO/2021/062199A1
Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.  
WO/2021/050672A1
Described herein are compounds that are kinase inhibitors. The disclosed compounds have improved properties that lead to specific targeting of kinases without inhibiting the activity of related enzymes including, making them useful for t...  
WO/2021/050555A1
The present invention relates to compositions and methods for the treatment of disorders that lead to accumulation of oxalate, such as primary hyperoxaluria 1.  
WO/2020/245213A1
The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising ...  
WO/2020/145250A1
[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.  
WO/2020/127390A1
A method is provided for preparing a compound d having the formula (D) The method comprises carrying out the following reaction (c) → (d), where the reaction is carried out at a temperature of at least 100 °C and in the presence of a ...  
WO/2020/127385A1
A method is provided for preparing a compound d having the formula: Formula (I). The method comprises carrying out the following reaction: Formula (i), (ii), (d) where: step (i) is carried out in the presence of a metal catalyst and a hy...  
WO/2020/018547A1
The present disclosure relates to methods for treating lupus nephritis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxam ide compounds of Formula (I), including pharm...  
WO/2020/018551A1
The present disclosure relates to methods for treating inflammatory bowel disease, with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxam ide compounds of Formula (I), inc...  
WO/2018/213491A9
The present invention is directed to, in part, methods of preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. In so...  
WO/2019/141229A1
The present invention involves compounds as PPAR agonists and applications thereof. The compounds involved are novel peroxisome proliferator-activated receptor (PPAR) γ receptor agonists and can inhibit the production of mitochondrial r...  
WO/2019/082910A1
Provided are: a V2 receptor antagonist which has high water solubility and which is particularly suitable for injections; and a medicine containing the V2 receptor antagonist or the like. The present invention is a compound represented b...  
WO/2018/235926A1
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...  
WO/2018/213491A1
The present invention is directed to, in part, methods of preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. In so...  
WO/2018/193117A1
This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using ...  
WO/2018/115421A1
The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).  
WO/2018/104766A1
The present invention relates to compounds of Formula (I), and Formula (II), wherein B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH2)2-triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents indepe...  
WO/2018/007973A3
Disclosed is a new process and intermediates for preparing benzoxazepines of Formula (I): (I) wherein Q is, and A, L, B, RA and m are as defined herein.  
WO/2018/022978A1
The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carbox...  
WO/2018/007973A2
Disclosed is a new process and intermediates for preparing benzoxazepines of Formula (I): (I) wherein Q is, and A, L, B, RA and m are as defined herein.  
WO/2018/009417A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.  
WO/2017/205536A3
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical composition...  
WO/2017/222083A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their p...  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/205536A2
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compou...  
WO/2017/132752A1
A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in...  
WO/2017/098430A1
The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new c...  
WO/2016/203401A1
The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.  
WO/2016/198366A1
The instant invention relates to novel conjugates of formula (I): S - L - A (I) or salts thereof, wherein A is a gamma-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture...  
WO/2015/123519A9
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.  
WO/2016/149581A1
Provided herein are compounds of formula (I) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2015/123519A8
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.  
WO/2016/126725A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:, where R, L, X1, X2, X3, X4, Y1, Y2, Y...  
WO/2016/126722A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: (Formula I should be inserted here) wh...  
WO/2016/126726A1
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: where R, L, X1, X2, X3,X4, X5, Y1, Y2, ...  
WO/2016/126721A1
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I:(Formula I should be inserted here), where R, L, X1, X2...  
WO/2016/126724A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:(Formula I should be inserted here) whe...  
WO/2016/087370A1
The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use...  
WO/2016/075239A1
The invention relates to aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amide derivatives of general formula (l),which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders relat...  
WO/2016/075240A1
The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addit...  
WO/2016/055028A1
The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300....  
WO/2016/019588A1
Compounds, compositions, and methods for treating C. difficile are provided.  
WO/2016/012333A1
A method of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or moll...  
WO/2015/123519A3
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.  
WO/2015/138500A1
A genus of arylsulfonamide derivatives of aminocycloalkanols is disclosed. The compounds are of the following genus (I):. The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequen...  
WO/2015/123519A2
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.  
WO/2015/110826A1
The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), (Formula (I)) that inhibit dipeptidyl peptidase 1(DPP1) activity,...  
WO/2015/109130A1
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2015/056782A1
The purpose of the present invention is to provide a novel compound having ACC2-inhibiting activity and to provide a pharmaceutical composition comprising said compound. A compound indicated by formula (in the formula, R1 indicates a sub...  
WO/2014/133414A3
1. Compounds of general formula I, or racemic mixtures thereof, or individual optical isomers thereof, or pharmaceutically acceptable salts and/or hydrates thereof, wherein: X is the amino group R'R''N, optionally substituted or unsubsti...  

Matches 1 - 50 out of 1,187